Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.38 |
| ▸ | PDE8B | O95263 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136783 | 0.88 | ALDH1A1 (0.42) | ALDH1A1ADORA2AADORA2BPDE8BPDE4B | |
| SCHEMBL30731519 | 0.86 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BTMIGD3PDE8B | |
| SCHEMBL3324519 | 0.86 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BTMIGD3PDE8B | |
| SCHEMBL3322870 | 0.86 | ADORA2A (0.43) | ALDH1A1ADORA2AADORA1ADORA2BTMIGD3 | |
| SCHEMBL2198592 | 0.82 | TLR7 (0.41) | ADORA2AADORA1ADORA2BPDE8BADORA3 | |
| SCHEMBL4136423 | 0.80 | ALDH1A1 (0.49) | ALDH1A1ADORA2AADORA2BFLT3MEN1 | |
| SCHEMBL3378114 | 0.77 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BTMIGD3PDE8B | |
| SCHEMBL16882930 | 0.77 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BTMIGD3PDE8B | |
| SCHEMBL1848717 | 0.77 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BTMIGD3PDE8B | |
| SCHEMBL2200724 | 0.77 | ADORA2A (0.41) | ALDH1A1ADORA2AADORA2BPDE8BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | ALDH1A1 115/4885ADORA2A 2/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.